Table 2.
Characteristics of selected studies. Sub-studies are grouped with the main study.
| Refs. | First Author, Year Trial Registration Number |
Country | Study Design | Study Group | Time |
|---|---|---|---|---|---|
| [22] | Dörr et al., 2020 NCT01440062 |
Germany | Randomized, double-blind low-dose controlled |
Interferon (IFN)-β1b RRMS/CIS |
Not provided |
| [21,43] | Hupperts et al., 2019 Rolf et al., 2017 NCT01285401 |
11 European countries | Randomized, double-blind, placebo-controlled |
IFN-β1a- treated RRMS |
February 2011 to May 2015 |
| [23] | Camu et al., 2019 NCT01198132 |
France | Randomized, double-blind, placebo-controlled |
RRMS | January 2010 to June 2013 |
| [31] | Kotb et al., 2019 | Saudi Arabia | Uncontrolled | RRMS | 2013–2018 |
| [32] | Darwish et al., 2017 NCT01952483 |
Lebanon | Uncontrolled | RRMS/CIS | Not provided |
| [27] | O’Connell et al., 2017 NCT01728922 |
Ireland | Randomized, double-blind, placebo-controlled |
CIS | November 2012 to June 2015 |
| [28] | Laursen et al., 2016 | Denmark | Uncontrolled | Natalizumab-treated RRMS | 2009–2010 |
| [39] | Sotirchos et al., 2016 NCT01024777 |
USA | Randomized, double-blind, low-dose-controlled |
RRMS | April 2010 to January 2013 |
| [35,44] | Farsani et al., 2015 Naghavi Gargari et al., 2015 IRCT2014011216181N1 |
Iran | Uncontrolled | RRMS | November 2012 to October 2013 |
| [36] | Etemadifar et al., 2015 | Iran | Randomized, open-label, routine care-controlled |
Pregnant women with MS | July 2011 to December 2012 |
| [33] | Achiron et al., 2015 | Israel | Randomized, double-blind, placebo-controlled |
MS | Not provided |
| [34,45] | Golan et al., 2013a and 2013b NCT01005095 |
Israel | Randomized, double-blind, low-dose-controlled |
RRMS | November 2010 to April 2012 |
| [29,46] | Soilu-Hänninen et al., 2012 Hänninen et al., 2020 NCT01339676 |
Finland | Randomized, double-blind, placebo-controlled |
IFN-treated RRMS | March 2008 to August 2011 |
| [30] | Kampman et al., 2012 NCT00785473 |
Norway | Randomized, double-blind, placebo-controlled |
MS | November 2008 to September 2011 |
| [37] | Shaygannejad et al., 2012 IRCT201104166202N1 |
Iran | Randomized, double-blind, placebo-controlled |
RRMS | October 2007 to October 2008 |
| [42] | Stein et al., 2011 ACTRN12606000359538 |
Australia | Randomized, double-blind, low-dose-controlled |
RRMS | December 2006 to May 2009 |
| [38] | Mosayebi et al., 2011 | Iran | Randomized, double-blind, placebo-controlled |
IFN-treated MS |
October 2009 to April 2011 |
| [40,47] | Kimball et al., 2007 Burton et al., 2010 NCT00644904 |
Canada | Randomized, open-label, controlled | RRMS | December 2003 to January 2005 |
| [41] | Wingerchuk et al., 2005 | USA | Uncontrolled | RRMS | March 1999 to March 2001 |